Cargando…

Acetaminophen pharmacokinetics in infants and children with congenital heart disease

BACKGROUND: Acetaminophen is routinely used for perioperative analgesia in children undergoing major surgical procedures. There are few estimates of acetaminophen pharmacokinetic parameters in children with congenital heart disease, especially those with cyanotic heart disease. AIMS: The current stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Holladay, Jay, Winch, Peter, Morse, James, Anderson, Brian J., McKee, Christopher T., Rice‐Weimer, Julie, Tobias, Joseph D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100048/
https://www.ncbi.nlm.nih.gov/pubmed/36264219
http://dx.doi.org/10.1111/pan.14579
_version_ 1785025191994195968
author Holladay, Jay
Winch, Peter
Morse, James
Anderson, Brian J.
McKee, Christopher T.
Rice‐Weimer, Julie
Tobias, Joseph D.
author_facet Holladay, Jay
Winch, Peter
Morse, James
Anderson, Brian J.
McKee, Christopher T.
Rice‐Weimer, Julie
Tobias, Joseph D.
author_sort Holladay, Jay
collection PubMed
description BACKGROUND: Acetaminophen is routinely used for perioperative analgesia in children undergoing major surgical procedures. There are few estimates of acetaminophen pharmacokinetic parameters in children with congenital heart disease, especially those with cyanotic heart disease. AIMS: The current study prospectively investigated differences in acetaminophen pharmacokinetics following surgery using cardiopulmonary bypass in children with cyanotic and acyanotic congenital heart disease. METHODS: Children (2–6 years, 9–23 kg) presenting for median sternotomy for Fontan palliation (cyanotic patients) or two ventricle surgical repair (acyanotic patients) were eligible for inclusion. A single intravenous dose of acetaminophen (15 mg/kg) was administered at the start of sternal closure after separation from cardiopulmonary bypass. The time‐course of acetaminophen concentrations were described using non‐linear mixed effects models. One and two‐compartment disposition models with first‐order elimination were tested. Pharmacokinetic parameter estimates were scaled using allometry and standardized to a 70 kg person. RESULTS: There were 208 acetaminophen concentrations assayed from 30 children, 15 with cyanotic, and 15 with acyanotic heart disease. A 2‐compartment model best described acetaminophen PK. Parameter estimates (population parameter variability, PPV%; 95% confidence interval, CI) were clearance CL 15.3 L.h‐1.70 kg‐1 (22.2%; 13.8–16.7), intercompartment clearance Q 45.4 L.h‐1.70 kg‐1 (22.4%; 25.2–61.9), central volume of distribution V1 33.5 L.70 kg‐1 (23.2%; 25.9–38.8), peripheral volume of distribution V2 32.1 L.70 kg(−1) (21.7%; 25.9–38.8). Neither clearance nor volume parameters differed between cyanotic and acyanotic patients. CONCLUSIONS: Acetaminophen pharmacokinetics were characterized using a 2‐compartment model with first‐order elimination following cardiac bypass surgery in children. Population pharmacokinetic parameter estimates were similar to other studies in children. No differences were detected between patients with cyanotic and acyanotic heart disease.
format Online
Article
Text
id pubmed-10100048
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-101000482023-04-14 Acetaminophen pharmacokinetics in infants and children with congenital heart disease Holladay, Jay Winch, Peter Morse, James Anderson, Brian J. McKee, Christopher T. Rice‐Weimer, Julie Tobias, Joseph D. Paediatr Anaesth Research Reports BACKGROUND: Acetaminophen is routinely used for perioperative analgesia in children undergoing major surgical procedures. There are few estimates of acetaminophen pharmacokinetic parameters in children with congenital heart disease, especially those with cyanotic heart disease. AIMS: The current study prospectively investigated differences in acetaminophen pharmacokinetics following surgery using cardiopulmonary bypass in children with cyanotic and acyanotic congenital heart disease. METHODS: Children (2–6 years, 9–23 kg) presenting for median sternotomy for Fontan palliation (cyanotic patients) or two ventricle surgical repair (acyanotic patients) were eligible for inclusion. A single intravenous dose of acetaminophen (15 mg/kg) was administered at the start of sternal closure after separation from cardiopulmonary bypass. The time‐course of acetaminophen concentrations were described using non‐linear mixed effects models. One and two‐compartment disposition models with first‐order elimination were tested. Pharmacokinetic parameter estimates were scaled using allometry and standardized to a 70 kg person. RESULTS: There were 208 acetaminophen concentrations assayed from 30 children, 15 with cyanotic, and 15 with acyanotic heart disease. A 2‐compartment model best described acetaminophen PK. Parameter estimates (population parameter variability, PPV%; 95% confidence interval, CI) were clearance CL 15.3 L.h‐1.70 kg‐1 (22.2%; 13.8–16.7), intercompartment clearance Q 45.4 L.h‐1.70 kg‐1 (22.4%; 25.2–61.9), central volume of distribution V1 33.5 L.70 kg‐1 (23.2%; 25.9–38.8), peripheral volume of distribution V2 32.1 L.70 kg(−1) (21.7%; 25.9–38.8). Neither clearance nor volume parameters differed between cyanotic and acyanotic patients. CONCLUSIONS: Acetaminophen pharmacokinetics were characterized using a 2‐compartment model with first‐order elimination following cardiac bypass surgery in children. Population pharmacokinetic parameter estimates were similar to other studies in children. No differences were detected between patients with cyanotic and acyanotic heart disease. John Wiley and Sons Inc. 2022-11-07 2023-01 /pmc/articles/PMC10100048/ /pubmed/36264219 http://dx.doi.org/10.1111/pan.14579 Text en © 2022 The Authors. Pediatric Anesthesia published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research Reports
Holladay, Jay
Winch, Peter
Morse, James
Anderson, Brian J.
McKee, Christopher T.
Rice‐Weimer, Julie
Tobias, Joseph D.
Acetaminophen pharmacokinetics in infants and children with congenital heart disease
title Acetaminophen pharmacokinetics in infants and children with congenital heart disease
title_full Acetaminophen pharmacokinetics in infants and children with congenital heart disease
title_fullStr Acetaminophen pharmacokinetics in infants and children with congenital heart disease
title_full_unstemmed Acetaminophen pharmacokinetics in infants and children with congenital heart disease
title_short Acetaminophen pharmacokinetics in infants and children with congenital heart disease
title_sort acetaminophen pharmacokinetics in infants and children with congenital heart disease
topic Research Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100048/
https://www.ncbi.nlm.nih.gov/pubmed/36264219
http://dx.doi.org/10.1111/pan.14579
work_keys_str_mv AT holladayjay acetaminophenpharmacokineticsininfantsandchildrenwithcongenitalheartdisease
AT winchpeter acetaminophenpharmacokineticsininfantsandchildrenwithcongenitalheartdisease
AT morsejames acetaminophenpharmacokineticsininfantsandchildrenwithcongenitalheartdisease
AT andersonbrianj acetaminophenpharmacokineticsininfantsandchildrenwithcongenitalheartdisease
AT mckeechristophert acetaminophenpharmacokineticsininfantsandchildrenwithcongenitalheartdisease
AT riceweimerjulie acetaminophenpharmacokineticsininfantsandchildrenwithcongenitalheartdisease
AT tobiasjosephd acetaminophenpharmacokineticsininfantsandchildrenwithcongenitalheartdisease